N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, has announced that it has entered into a research collaboration agreement with SRI International, an independent nonprofit research institute based in Silicon Valley, California to combine Nuvec® with SRI’s proprietary FOX Three Molecular Guidance System™ (MGS) with the aim of co-marketing the resultant combined technology.
Under the Agreement, the Company will collaborate with SRI to perform research to conjugate its MGS system to Nuvec® in order to increase intracellular delivery to specific target cells. On the back of the combined technology, N4 Pharma and SRI will work collaboratively to develop and pursue new business opportunities.
